https://vimeo.com/330610777 https://vimeo.com/330611169
Myeloma NZ
Imaging in multiple myeloma: How? When?
Bone disease is the most frequent feature of multiple myeloma (MM) and represents a marker of end-organ damage; it is used to establish the...
Multiple Myeloma Research Review
Highlights include: Real-life safety and efficacy of autologous SCT in elderly MM Lenalidomide maintenance vs. observation for newly diagnosed MM...
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised,...
Going the distance: Are we losing patients along the multiple myeloma treatment pathway?
Despite data suggesting that individuals with multiple myeloma can benefit from receiving several lines of therapy, and guidelines recommending...
Single-cell Profiling in Multiple Myeloma May Improve Diagnosis, Treatment, Study Suggests
Analysis of thousands of individual cells in multiple myeloma patients allows for a much more precise diagnosis — distinguishing asymptomatic,...
Lenalidomide Maintenance Therapy for Multiple Myeloma
Orally administered lenalidomide, a second-generation antimyeloma thalidomide analog, is a workhorse in contemporary management of multiple myeloma:...
Myeloma Study Makes the Case for a New Standard for Predicting Long-Term Outcome
As new treatments for multiple myeloma have extended patient survival—from an average of three years to more than 10 in some cases—physicians and...
Increased Risk of Myeloma in African Americans Driven By Higher Rates of 3 Disease Subtypes
Multiple myeloma (MM)Â and monoclonal gammopathy of undetermined significance (MGUS), a precursor to MM, are 2 to 3 times more common in African...
THE ELUSIVE C-WORD: CURE?
Until now, myeloma patients whose cancer was resistant to commonly used treatment methods and drugs had nowhere to turn. But a Phase 2 CAR T-cell...
CAR T Cell Therapy Market to Reflect Impressive Growth Rate
Increasing incidence of cancer and rising number of patients showing response failure to alternative treatments is expected to foster growth of the...
Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
On January 3, 2019, Takeda announced multiple research collaborations involving the development of chimeric antigen receptor T-cell (CAR-T)...